Skip to main content
Home
About
About CPD Network
Mission & Vision
Purpose
Governance
Compliance
Physician Organization Checklist
Microsites
Experts
Members
Contact
Login
Home
About
About CPD Network
Mission & Vision
Purpose
Governance
Compliance
Physician Organization Checklist
Microsites
Experts
Members
Contact
Login
Home
Microsites
Evolution T2D
FR
EN
Program Materials
Program Slides
Speaker Tour Events
View online
|
Download
Program Slides
Regional Events
View online
|
Download
Program Bibliography
Download
Download Speaker Disclosure
Game Changers in the Management of T2D: An Overview
1. Milestones in the history of diabetes mellitus: The main contributors - Marianna Karamanou et al. (Nature Reviews Endocrinology 2021)
Game-changing Evidence for SGLT2 inhibitors and GLP1-RAs
1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes - Zinman B, et al. (N Engl J Med. 2015)
2. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes - Marso S, et al. (N Engl J Med. 2016)
3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes - Marso S, et al. (N Engl J Med. 2016)
4. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes - Neal B, et al. (N Engl J Med. 2017)
5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy - Perkovic V, et al. (N Engl J Med. 2019)
6. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - Gerstein HC, et al. (Lancet. 2019)
7. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes - Wiviott SD, et al. (N Engl J Med. 2019)
8. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction - McMurray JJ, et al. (N Engl J Med. 2019)
9. Dapagliflozin in Patients with Chronic Kidney Disease - Heerspink HJL, et al. (N Engl J Med. 2020)
10. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure - Packer M, et al. (N Engl J Med. 2020)
11. Empagliflozin in Heart Failure with a Preserved Ejection Fraction - Anker SD, et al. (N Engl J Med 2021)
12. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction - Solomon SD, et al. (N Engl J Med. 2022)
13. Empagliflozin in Patients with Chronic Kidney Disease - The EMPA-KIDNEY Collaborative Group (N Engl J Med. 2023)
The Game-changing Evolution of Incretin Therapy: GLP-1/GIP dual receptor agonism
1. The expanding incretin universe: from basic biology to clinical translation – Drucker D, et al. (Diabetologia 2023)
2. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Rosenstock et al, Lancet. 2021)
3. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - Frías JP, et al. (N Engl J Med. 2021)
4. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial (Ludvik et al, Lancet 2021)
5. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial (Del Prato et al, Lancet 2021)
6. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (Dahl et al, JAMA 2022)
Refining Priorities for T2D Management: Game Changing Guidelines and Recommendations
1. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update - Lipscombe L, et al. (Can J Diabetes 2020)
2. Blood Glucose Monitoring in Adults and Children with Diabetes: Update 2021 - Cheng AYY, et al. (Can J Diabetes 2021)
3. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
4. Remission of Type 2 Diabetes: Diabetes Canada Clinical Practice Guidelines Expert Working Group - Mackay D, et al. (Can J Diabetes 2022)
Exit
cpdisup
